Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs Standard of Care in People Living with Hereditary Angioedema
Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: The CHAPTER-1 Open-Label Extension Study
Dec 14, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Prophylaxis of Hereditary Angioedema Attacks With Oral Deucrictibant: Efficacy and Quality-of-Life Results from CHAPTER-1
Dec 13, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
RAPIDe-2 Study: Long-term Efficacy and Safety of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks
Nov 20, 2024
Source:
ISPOR Europe 2024, Barcelona
Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results
Nov 07, 2024
Source:
SEAIC 2024, Bilbao, Spain
Investigating the Burden of Disease in People Living With Hereditary Angioedema and their Caregivers in Europe
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial
Nov 07, 2024
Source:
SEAIC 2024, Bilbao, Spain
Characterizing Patient Treatment of Hereditary Angioedema Airway Attacks
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders 
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders 
Oct 20, 2024
Source:
JSA 2024, Kyoto
Efficacy and Safety of Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema: RAPIDe-3 Phase 3 Clinical Trial Design
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Relief and Resolution of Hereditary Angioedema Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life in Patients With Hereditary Angioedema
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Characterizing Use of On-Demand Treatment Among People Living With Hereditary Angioedema in Germany
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Prophylactic treatment with oral deucrictibant improves health-related quality of life in patients with hereditary angioedema
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Sep 14, 2024
Source:
CIIC Fall 2024, Dallas, Texas, U.S.
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Sep 13, 2024
Source:
CIIC Fall 2024, Dallas, Texas, U.S.
Long-Term Safety and Efficacy of Prophylactic Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Hereditary Angioedema: Results of the CHAPTER-1 Open Label Extension Study
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Deucrictibant Inhibits Carrageenan-Induced Edema in Bradykinin B2 Receptor Transgenic Rat
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
The bradykinin challenge model translates across rat, monkey and human
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Clinical Trials Conformity with AURORA COS: a systematic literature review
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
Sep 06, 2024
Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Treatment of HAE attacks with oral deucrictibant: RAPIDe-2 extension results
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Long-term safety and efficacy of oral deucrictibant for HAE prophylaxis
Sep 05, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Prophylactic Treatment With Deucrictibant Improves HAE Disease Control and HRQoL
Sep 05, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat
Jun 01, 2024
Source:
EAACI 2024, Valencia, Spain
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Jun 01, 2024
Source:
EAACI 2024, Valencia, Spain
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Jun 01, 2024
Source:
EAC 2024, Palm Springs, FL
Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema
May 22, 2024
Source:
IDDST 2024, Osaka, Japan
Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Mar 16, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Understanding the Reasons not to Treat All HAE Attacks and Patient Satisfaction for on-Demand Treatment (ODT). Results from the HAE Wave II Disease Specific Program™ (DSP™) 2023.
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S
Nov 11, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data
Nov 10, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations
Oct 23, 2023
Source:
APAAACI 2023 International Conference, Singapore
Bradykinin B2 receptor antagonist deucrictibant immediate-release capsule for treatment of HAE attacks: Phase 2
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Sep 02, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: CHAPTER-1 phase 2 trial design
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
May 05, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Mar 18, 2023
Source:
2023 HAEi Regional Conference APAC, Bangkok
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Feb 26, 2023
Source:
2023 AAAAI Annual Meeting, San Antonio, TX
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Nov 13, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Nov 12, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Oct 07, 2022
Source:
2022 HAEi Global Leadership Workshop, Frankfurt
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Sep 16, 2022
Source:
Bradykinin Symposium 2022, Berlin
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Jun 07, 2022
Source:
Satellite Symposium Kinin 2022
Tailored drug development for patients living with HAE
Mar 22, 2022
Source:
International Immunopharmacology
In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development
Jul 10, 2021
Source:
EAACI Annual Congress 2021, Virtual
Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAE
Jun 04, 2021
Source:
12th C1-inhibitor Deficiency and Angioedema Workshop, Virtual
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Feb 26, 2021
Source:
2021 AAAAI Annual Meeting, Virtual
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Jul 30, 2020
Source:
Frontiers in Pharmacology
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Apr 09, 2020
Source:
2020 AAAAI Annual Meeting, Virtual
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model